Bill.com Holdings Inc vs Medpace Holdings Inc — how do they compare? Bill.com Holdings Inc trades at $49.45 (market cap $4.93B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: Medpace Holdings Inc is far larger — about 3.4× Bill.com Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Bill.com Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BILL | MEDP | |
|---|---|---|
Market Cap | $4.93B | $16.90B |
Sector | Technology | Technology |
52-Week High | $56.32 | $620.59 |
52-Week Low | $31.96 | $393.42 |
Enterprise Value | $4.64B | $16.52B |
Signals from Pluang's Aura AI — not financial advice
BILL Holdings trades at $48.63, down 1.28% on the day, with a bullish technical signal from moving averages and positive earnings beats in recent quarters. Revenue growth is strong, reaching $1.46B in 2025, but profitability remains thin with a net income margin of just 0.01%. The company is focusing on AI-driven automation and operational efficiency, including a recent 30% workforce reduction and new executive appointments to spur growth.
Outlook is cautiously optimistic given analyst consensus favoring Buy ratings (56%) and a price target implying modest upside. Key risks include intense fintech competition and the challenge of translating high revenue into sustained profitability. Cash flow trends show improvement, but investors should monitor execution on margin expansion and competitive positioning.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →